Vaccines & beyond: a decade in mRNA delivery

David McCall, Commissioning Editor, BioInsights, speaks to
Russell Johnson, former Vice President, Formulation Research, RVAC Medicines

Russell Johnson was until recently the Vice President of Formulation Research at RVAC Medicines, a clinical stage mRNA-focused healthcare company with a strategic focus on global health. He brings more than 10 years of industrial R&D experience in the delivery of RNA in preclinical and clinical programs. Prior to RVAC, Russell was the local-head of drug product discovery at GSK’s US-Vaccine Research center and worked across GSK’s vaccine technologies and platforms. He has deep experience in lipid, polymeric, and inorganic nanoparticles used for a variety of mRNA delivery, with more than 40 peer-reviewed publications and presentations.

Please enter your email to access content Read now